- Exchange: NASDAQ GM
- Sector: Consumer, Non-cyclical
- Industry: Healthcare-Products
- Sub-Industry: Medical Products
Snapshot for Cerus Corp (CERS)
| Open: | 5.0500 | Day's Range: | 5.0500 - 5.1900 | Volume: | 238,068 |
|---|---|---|---|---|---|
| Previous Close: | 5.1600 | 52wk Range: | 2.6800 - 5.5800 | 1-Yr Rtn: | +47.85% |
Key Statistics for CERS
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (USD) (ttm) | -0.3800 |
| Est. EPS (USD) (12/2013) | -0.4160 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 359.73 |
| Shares Outstanding (M) | 69.72 |
| 30 Day Average Volume | 633,940 |
| Price/Book (mrq) | 5.9179 |
| Price/Sale (ttm) | 7.6789 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/02/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for CERS
Company Profile & Key Executives for CERS
Cerus Corporation develops systems designed to enhance the safety of blood transfusions. The Company's systems inactivate pathogens in blood components and inactivate white blood cells, which are responsible for a variety of adverse transfusion reactions. Cerus' platform technologies prevent viral, bacterial, and cellular replication.
| William Mariner Greenman "Obi"President/CEO | Caspar HogeboomPres:Cerus Europe |
| Laurence M CorashSenior VP/Chief Medical Ofcr | Kevin D GreenVP:Finance/CFO |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
CERS News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page